Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Freeman-Keller, Morganna, Kim, Youngchul, Cronin, Heather, Richards, Allison, Gibney, Geoffrey, Weber, Jeffrey S.·2016·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-15-1136

Cited by (860)

Items 501–600 of 860

The immunology of vitiligo
Mary Jo Turk, Yina H. Huang · 2026 · Nature reviews. Immunology
Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience
Renata Pacholczak‐Madej, Aleksandra Grela-Wojewoda, Mirosława Püsküllüoğlu, Joanna Lompart, Manuela Las‐Jankowska, Katarzyna Krawczak, Ewa Wrona, Lech Zaręba, Justyna Żubrowska, Jerzy Andrzej Walocha et al. · 2022 · Biomedicines
Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer
Yan Wu, Dapeng Li, Mengyao Wu, Ying Yang, Meng Shen, Kai Chen · 2022 · Frontiers in Oncology
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab
Anna K. Maloney, Anita Giobbie‐Hurder, Nikita Katukota, Miklos C. Fogarasi, Patrick Alexander Ott, F Stephen Hodi, Tamara A. Sussman, Ann Willman Silk, Rizwan Haq, David Liu et al. · 2024 · Journal for ImmunoTherapy of Cancer
The Incidence and Relative Risk of Pulmonary Toxicity in Patients Treated with Anti-PD1/PD-L1 Therapy for Solid Tumors: A Meta-Analysis of Current Studies
Chiara Ciccarese, Roberto Iacovelli, Emilio Bria, Alessandra Modena, Francesco Massari, Matteo Brunelli, Emanuela Fantinel, Davide Bimbatti, Giulia Angela Zamboni, Walter Artibani et al. · 2017 · Immunotherapy
Challenging Cases: Management of Immune-Related Toxicity
Jeffrey S. Weber · 2018 · American Society of Clinical Oncology Educational Book
Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events
Machiko Kawahira, Shuji Kanmura, Keiko Mizuno, Kentaro Machida, Takao Ohtsuka, Masami Sato, Hideki Enokida, Masaru Yamashita, Takuro Kanekura, Shiho Arima et al. · 2022 · PLoS ONE
Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma
C. Boutros, Djaouida Belkadi-Sadou, A. Marchand, Séverine Roy, Émilie Routier, Caroline Robert · 2023 · Current Oncology Reports
Treating tumors with immune checkpoint inhibitors: Rationale and limitations
Judith Anna Seidel, Atsushi Otsuka, Kenji Kabashima · 2017 · Trends in Immunotherapy
Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?
Tri Le, John Dorrance Minna, David E. Gerber · 2019 · Journal of Thoracic Oncology
Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases
YUMIKO AKANO, Kozo Kuribayashi, Norihiko Funaguchi, Yuichi Koda, Eriko Fujimoto, Koji Mikami, Toshiyuki Minami, Ryo Takahashi, Takashi Yokoi, Takashi Kijima · 2019 · In Vivo
Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy
Takuya Maeda, Koji Yoshino, Kojiro Nagai, Satoe Oaku, Megumi Kato, Azusa Hiura, Hiroo Hata · 2019 · European Journal of Cancer
Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune‐related adverse events after immune checkpoint inhibitor therapy
Nikki Burdett, Kristin Hsu, Libo Xiong, Gonzalo Tapia Rico, Kerri Beckmann, Christos Stelios Karapetis, Michael Paul Brown · 2019 · Asia-Pacific Journal of Clinical Oncology
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies
L. Dousset, Katia Boniface, Julien Sénéschal · 2019 · Giornale Italiano di Dermatologia e Venereologia
Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma
Nozomi Hayakawa, Eiji Kikuchi, Shigeaki Suzuki, Mototsugu Oya · 2020 · International Cancer Conference Journal
A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient
Yukino Yatsuda, Suguru Hirose, Yoshimi Ito, Tsubasa Onoda, Yutaro Sugiyama, Miho Nagafuchi, Hirosumi Suzuki, Yusuke Niisato, Yoshitaka Tange, Takafumi Ikeda et al. · 2020 · Internal Medicine
Checkpoint inhibitor pneumonitis in Chinese lung cancer patients: clinical characteristics and risk factors
Chen Zhang, Fangyan Gao, Shidai Jin, Wen Gao, Shuangjing Chen, Renhua Guo · 2020 · Annals of Palliative Medicine
Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
Sae Ohwada, Keisuke Ishigami, Noriyuki Akutsu, Hiroshi Nakase · 2022 · Biomedicines
Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment
Charlée Nardin, F. Pelletier, Eve Puzenat, François Aubin · 2019 · Acta Dermato Venereologica
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases
Michael Zhang, Adrian John Rodrigues, Erqi Liu Pollom, Iris C. Gibbs, Scott G. Soltys, Steven L. Hancock, Joel W. Neal, Sukhmani Kaur Padda, Kavitha J. Ramchandran, Heather A. Wakelee et al. · 2021 · Journal of Neuro-Oncology
The epidemic of drug‐induced sarcoidosis‐like reactions: a side effect that we can live with
Marc A. Judson · 2019 · Journal of Internal Medicine
Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency
Yukino Katakura, Tomohiko Kimura, Takashi Kusano, Fuminori Tatsumi, Yuichiro Iwamoto, Junpei Sanada, Yoshiro Fushimi, Masashi Shimoda, Kenji Kohara, Shuhei Nakanishi et al. · 2021 · Frontiers in Endocrinology
Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists
Renata Pacholczak‐Madej, Joanna Kosałka-Węgiel, Piotr Kuszmiersz, Jerzy Władysław Mituś, Mirosława Püsküllüoğlu, Aleksandra Grela-Wojewoda, Mariusz Korkosz, Stanisława Bazan‐Socha · 2023 · International Journal of Environmental Research and Public Health
Impact of comorbidities on outcomes in patients with advanced head and neck cancer undergoing immunotherapy
Meytal Guller, Dylan Jacob Cooper, Hosam H. Alkhatib, Aditya Suru, Angelo Blancaflor, Christopher A. Maroun, Tristan Tham, Hailey Allen, Eden Mazzara, Jerin Thomas et al. · 2023 · Head & Neck
Risk of reactive cutaneous capillary endothelial proliferation induced by camrelizumab in patients with non-small cell lung cancer: a retrospective study
Xuan He, Jie Fang, Ping Yü, Weiting Hu, Qiurui Zhang, Ze Zhang, Min Zhou, Xiaofei Wang, Xiaolan Bian · 2023 · Journal of Thoracic Disease
Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study
Jie Zhao, Yongzhong Guo, Tianshuo Feng, Dawei Rong, Xiangyi Kong, Tian Huang, Víctor López‐López, Hooman Yarmohammadi, Yoshihiro Sakamoto, Deming Zhu et al. · 2023 · Journal of Gastrointestinal Oncology
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Federico Rossari, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier et al. · 2024 · Targeted Oncology
Clinical Management and Outcomes of Immune-Related Adverse Events During Treatment with Immune Checkpoint Inhibitor Therapies in Melanoma and Renal Cell Carcinoma: A UK Real-World Evidence Study
Anna Claire Olsson-Brown, Ankit Jain, Ricky Dylan Frazer, David Farrugia, Judith Carser, John B. Houghton, Ruth D. Lewis, Simon D'Mello, Gabrielle Emanuel · 2025 · Oncology and Therapy
Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab
Kenji Ishido, Satoshi Tanabe, Chikatoshi Katada, Yu Ishibashi, Gen Kitahara, Mie Onoue, Yo Kubota, Yasuaki Furue, Takuya Wada, Akinori Watanabe et al. · 2022 · Journal of Gastrointestinal Cancer
Immune checkpoint inhibitor-related thyroid dysfunction
F. Illouz, Claire Briet, Patrice Rodien · 2023 · Annales d Endocrinologie
Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches
Robert R. Flavell, Michael J. Evans, Javier E. Villanueva-Meyer, Sue Sun Yom · 2020 · International Journal of Radiation Oncology*Biology*Physics
Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: Consequences on overall survival
Leslie Adda, Benjamin Batteux, Zuzana Saidak, Claire Poulet, Jean‐Philippe Arnault, Bruno Chauffert, Alice Séjourné · 2021 · Joint Bone Spine
Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis
Karin Tina Mayer, Wibke Briese, Johannes Blieninger, Peter Brossart, Savita Bisht, Georg Feldmann · 2021 · Oncology Research and Treatment
A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution
Wylie M. Masterson, Alexandria M. Brown, May Ameri, Anisha B. Patel · 2022 · Cancer Treatment and Research Communications
Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study
Sakiko Aso, Nao Kawamura, Hideki Yanagida, Kazuko Nakajima, Hiroshi Ishikawa, Shota Omori, Haruyasu Murakami, Toshiaki Takahashi, Tateaki Naito · 2022 · Asia-Pacific Journal of Oncology Nursing
Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer
Ruifeng Chen, Kasim Hakimi, Xinlian Zhang, Karen S. Messer, Sandip Pravin Patel · 2022 · The Oncologist
Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management
Jonathan W. Lo, Hannah L. Hanania, Monika F. Keiser, Anisha B. Patel · 2023 · Archives of Dermatological Research
Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
Flávia Sardela de Miranda, Maribel Castro, Nicole Remmert, Sharda Prakash Singh, Rakhshanda Layeequr Rahman, Michael W. Melkus · 2023 · Frontiers in Immunology
Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives
Alberto Savino, Alberto Rossi, Stefano FAGIUOLI, Pietro Invernizzi, Alessio Gerussi, Mauro Viganò · 2024 · Cancers
Impact of nivolumab monotherapy infusion time-of-day on short- and long-term outcomes in patients with metastatic gastric cancer
Yasunobu Ishizuka, Yukiya Narita, Tomoki Sakakida, Munehiro Wakabayashi, Hiroko Kodama, Kazunori Honda, Toshiki Masuishi, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando et al. · 2025 · Therapeutic Advances in Medical Oncology
Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash
Pradnya Dinkar Patil, Anthony Patrick Fernandez, Vamsidhar Velcheti, Ahmad A. Tarhini, Pauline Funchain, Brian I. Rini, Mohamad K. Khasawneh, Nathan A. Pennell · 2018 · The Oncologist
Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
Anna Dawidowska, Paulina Jagodzińska-Mucha, Hanna Koseła-Paterczyk, S. Jaczewska, Paweł Sobczuk, Monika Chełstowska, Maria Małgorzata Kowalska, Honorata Badziak-Sterczewska, Jan Poleszczuk, Piotr Lukasz Rutkowski et al. · 2022 · Cancers
Detection of novel therapies using a multi‐national , multi‐institutional registry of cutaneous immune‐related adverse events and management
Rohan Mital, T. Otto, Andrei N. Savu, Emily Baumrin, Adela Rambi Cardones, Marta Carlesimo, Gemma Caro, Azael Freites‐Martínez, Jesse P. Hirner, Alina Markova et al. · 2023 · International Journal of Dermatology
Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review
Shun Sato, Taku Aoki, Takatsugu Matsumoto, Takayuki Shiraki, Shozo Mori, Yukihiro Iso, Takehiko Nemoto, Toshihiko Onishi, Makoto Iijima, Kazuyuki Ishida · 2023 · Clinical Journal of Gastroenterology
The good, the (not so) bad and the ugly of immune homeostasis in melanoma
Jessica Da Gama Duarte, Katherine Woods, Miles Cameron Andrews, Andreas Behren · 2018 · Immunology and Cell Biology
Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations
Katherine C. Kurnit, Pankti D. Reid, John William Moroney, Gini F. Fleming · 2020 · Gynecologic Oncology
Skin Reactions to Immune Checkpoint Inhibitors
Anisha B. Patel, Omar Pacha · 2021 · Advances in experimental medicine and biology
Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study
Saara Kuusisalo, Jussi Pekka Koivunen, Sanna Iivanainen · 2022 · Cancers
Skin Reactions to Immune Checkpoint Inhibitors
Anisha B. Patel, Omar Pacha · 2020 · Advances in experimental medicine and biology
Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report
Takayoshi Fuu, Kazuyoshi Iijima, Yukiko Kusama, Toshiaki Otsuki, Haruaki Kato · 2022 · Journal of Medical Case Reports
Dermatological adverse events under programmed cell death‐1 inhibitors as a prognostic marker in metastatic melanoma
Rony Shreberk‐Hassidim, Lilach Aizenbud, Shalev Lussheimer, Elena Thomaidou, Tali Bdolah‐Abram, Sharon Merims, Aron Popovtzer, Alex Maly, Michal Lotem, Abraham Zlotogorski · 2022 · Dermatologic Therapy
Immune-related thyroid dysfunction is associated with improved long-term prognosis in patients with non-small cell lung cancer treated with immunotherapy: a systematic review and meta-analysis
Zhengjun Li, Ying Xia, Mozhu Xia, Chang Xin Liu, Tao Wang, Yongyu Liu, Yi Ren · 2023 · Journal of Thoracic Disease
The immune‐related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials
Daniele Robesti, Luigi Nocera, Federico Belladelli, Julianne G. Schultz, Giuseppe Fallara, Laura Marandino, Daniele Raggi, Francesco Montorsi, Pavlos Msaouel, Andrea Necchi et al. · 2023 · British Journal of Urology
Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature
Hui Li, Xin Mei Zhou, Ding Zhang, Guoqiang Wang, Xiaochun Cheng, Caihong Xu, Bin Yao, Linrong Pang, Jun Chen · 2020 · Frontiers in Medicine
Immune checkpoint inhibitor‐related cutaneous adverse events
Chun‐Xia He, Tao Qu · 2020 · Asia-Pacific Journal of Clinical Oncology
Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients
Andrea Gawaz, I. Wolff, Lena Nanz, Lukas Flatz, Andrea Forschner · 2024 · Cancer Immunology Immunotherapy
The role of tumor types in immune-related adverse events
Qian Xu, Jing Hu, Yan Wang, Zhaohui Wang · 2024 · Clinical & Translational Oncology
Cutaneous Side Effects of PD ‐1 Inhibitors: A Single‐Center Retrospective Study
Melánia Pozsgai, Udoh Frieda‐Rex Sebastian, Péter Oláh, Viktória Németh, Rolland Gyulai, Zsuzsanna Lengyel · 2025 · International Journal of Dermatology
A Review of the Mechanisms and Clinical Implications of Precision Cancer Therapy–Related Toxicity: A Primer for the Radiologist
Richard Thomas, Stephanie Anne Holler Howard, Shawn L. Laferriere, Marta Braschi‐Amirfarzan · 2020 · American Journal of Roentgenology
Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies
Alexandra Frelau, Eva Jali, Boris Campillo‐Gimenez, Marc Pracht, Marc Porneuf, Monica Dinulescu, Julien Edeline, Lise Boussemart, Thierry Lesimple · 2021 · Melanoma Research
Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness
Susana Cortijo‐Cascajares, Ana Cristina Cercós-Lletí, Sara Ortiz-Pérez, José Manuel Caro Teller, José Miguel Ferrari-Piquero · 2021 · Journal of Oncology Pharmacy Practice
The many faces of autoimmune-mediated melanocyte destruction in melanoma
Loredana Ungureanu, Alina Florentina Vasilovici, Salomea-Ruth Halmágyi, Ioana Irina Trufin, Adina Patricia Apostu, Simona Corina Șenilă · 2024 · Frontiers in Immunology
Pharmacometrics and systems pharmacology of immune checkpoint inhibitor nivolumab in cancer translational medicine
Sujit Nair · 2016 · Advances in Modern Oncology Research
Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care
Chloe Goldman, Jeremy Tchack, Eric Michael Robinson, Sung Won Han, Una Moran, David Polsky, Russell S. Berman, Richard L. Shapiro, Patrick Alexander Ott, Iman Osman et al. · 2017 · Oncology
Vitiligo after immune checkpoint inhibitor therapy in a woman with metastatic melanoma
Ming-Han Yang, Dwan‐Ying Chang · 2018 · Journal of Cancer Research and Practice
Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy
Eric D. Johnson, Katie Kerrigan, Katerina Butler, Shiven B. Patel · 2019 · Journal of Oncology Pharmacy Practice
Immune-Mediated Colitis
Tara Menon, Anita Afzali · 2019 · Current Treatment Options in Gastroenterology
Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort
Doran Ksienski, Pauline T. Truong, Elaine S. Wai, Nicole S. Croteau, Angela M. Y. Chan, Tiffany Patterson, Melissa Clarkson, Samuel Hackett, Sarah Irons, Mary Lesperance · 2021 · Clinical Oncology
Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study
Kensei Yamaguchi, Narikazu Boku, Kei Muro, Kazuhiro Yoshida, Hideo Baba, Shinji Tanaka, Ayumi Akamatsu, Takeshi Sano · 2021 · Gastric Cancer
Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study
Fangmin Zhao, Rui Yu, Shuyi Chen, Shuya Zhao, Lin Sun, Zeting Xu, Yao Zhang, Shuying Dai, Gaochenxi Zhang, Qijin Shu · 2022 · Frontiers in Immunology
Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto et al. · 2022 · Targeted Oncology
Nomogram for tumour response based on prospective cohorts of hepatocellular carcinoma patients receiving immunotherapy combined with targeted therapy: development and validation
Qichen Chen, Yiqiao Deng, Chuanhua Zhao, Zhen Kun Huang, Wen Zhang, Yi An Yang, Yuxian Bai, Jianfei Tu, Bo Li, Wei Kelly Wu et al. · 2023 · Annals of Translational Medicine
Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune‐related adverse events and favorable outcome
Yushi Ueki, Shusuke Ohshima, Jo Omata, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii · 2023 · Cancer Medicine
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
Lisa Argnani, Beatrice Casadei, Carla Pelusi, Valentina Lo Preiato, Uberto Pagotto, Francesco Bertoni, Pier Luigi Zinzani · 2022 · Scientific Reports
Mendelian Randomization Analysis reveals Inverse Genetic Risks between Skin Cancers and Vitiligo
Sarem Rashid, Иван Игоревич Молотков, Nikolai Klebanov, Michael Shaughnessy, Mark J. Daly, Mykyta Artomov, Hensin Tsao · 2023 · JID Innovations
Safety and Efficacy of Immune Checkpoint Inhibitors in Human Immunodeficiency Virus-Associated Cancer: A Systematic Scoping Review
Ahmed D. Alatawi, Amirah B. Alaqyl, Reema J. Alalawi, Rahaf S. Alqarni, Razan A. Sufyani, Ghadi Saleh M Alqarni, Raghad Saleh Alqarni, Jumana H. Albalawi, Raghad A. Alsharif, Ghada I. Alatawi et al. · 2025 · Diseases
Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer
Carmen María Valencia Soto, María Victoria Villacañas Palomares, Adela García-Avello Fernández-Cueto, Sara Barbadillo Villanueva, Virginia Martínez Callejo, María Ochagavía Sufrategui, Pedro Muñoz, Marta Valero Domínguez · 2022 · European Journal of Hospital Pharmacy
Cardiovascular Immunotoxicity Associated with Immune Checkpoint Inhibitors in Metastatic Melanoma
J.‐M. L'Orphelin, Charles Dollalille, Julia Akroun, Joachim Alexandre, A. Dompmartin · 2023 · Cancers
Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions
Koki Uehara, Kenro Tanoue, Toshihiro Yamaguchi, Hirofumi Ohmura, Mamoru Ito, Yuzo Matsushita, Kenji Tsuchihashi, Shingo Tamura, Hozumi Shimokawa, Taichi Isobe et al. · 2023 · Cancer Immunology Immunotherapy
Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer
Jiří Blažek, Petr Hošek, Karolína Hrabcová, Monika Bratová, Juraj Kultan, Michal Hrnčiarik, Markéta Černovská, Petra Zemanová, Jana Krejčí, Leona Koubková et al. · 2023 · In Vivo
Personalised Medicine and the Potential Role of Electrospinning for Targeted Immunotherapeutics in Head and Neck Cancer
Connor H. O’Meara, Thanh Vinh Nguyen, Zuhayr Jafri, Michael Joseph Boyer, David C. Shonka, Levon Michael Khachigian · 2023 · Nanomaterials
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, Kenji Sawa, Yoshimasa Shiraishi, Ryota Saito, Junko Tanizaki, Yosuke Tamura, Akito Hata, Kosuke Tsuruno et al. · 2024 · British Journal of Cancer
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
Elias A. T. Koch, Anne Petzold, Edgar Dippel, Michael Erdmann, Anja Gesierich, Ralf Gutzmer, Jessica C. Hassel, Sebastian Haferkamp, Katharina Charlotte Kähler, Nicole Kreuzberg et al. · 2024 · Frontiers in Immunology
Management of checkpoint inhibitor-associated renal toxicities
Lowie Vanoverbeke, Ben Sprangers · 2017 · Expert Review of Quality of Life in Cancer Care
The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer
Courtney H. Coschi, Rosalyn Anne Juergens · 2021 · Current Oncology
Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival
Mario Giovanni Chilelli, Carlo Signorelli, Julio Rodrigo Giròn Berrìos, Angelo Onorato, Fabrizio Nelli, Agnese Fabbri, Francesca Primi, Eleonora Marrucci, Antonella Virtuoso, Marta Schirripa et al. · 2022 · Cancer Diagnosis & Prognosis
Rheumatic Complications of Immune Checkpoint Inhibitors
Nilasha Ghosh, Anne R. Bass · 2022 · Rheumatic Disease Clinics of North America
The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
Keiko Tanimura, Tadaaki Yamada, Yusuke Chihara, Yutaka Kubota, Shinsuke Shiotsu, Takayuki Takeda, Takahiro Yamada, Osamu Hiranuma, Junji Uchino, Koichi Takayama · 2019 · Haigan
Acute coronary syndrome and recurrent colitis as immune-related adverse events in a lung cancer patient
Bárbara Cancela-Díez, Félix Gómez-De Rueda, María J. Antolinos Pérez, Alberto Jiménez-Morales, Javier Luis López Hidalgo · 2019 · Journal of Oncology Pharmacy Practice
New and Worsening Long‐term Immune‐Related Adverse Events with PD‐1/PD‐L1 Pathway Agents in Patients with Cancer
Kevin H. Hall, Yuan Liu, Chen Jiang, Robert Donald Harvey · 2019 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Rheumatic Complications of Immune Checkpoint Inhibitors
Nilasha Ghosh, Anne R. Bass · 2021 · Medical Clinics of North America
Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors
Jarushka Naidoo, Douglas Buckner Johnson, Charlotte Doran, Yuexi Wang, Yan Zhang, Trong Kim Le, Sari D. Hopson, Brian Dreyfus, Lincy Subha Lal, Charmy Vyas et al. · 2024 · The Oncologist
Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity
J. B. Justice, Roma A. Kankaria, Douglas Buckner Johnson · 2024 · Expert Review of Clinical Pharmacology
Managing toxicities associated with immune checkpoint inhibitors
Jiyeon Joy Park, Syed Arafath, Samir T Kumar, Roopali Sharma, Deepali Dixit · 2021 · JAAPA
Immune checkpoint inhibitors: current status
Ana Filipa Palma dos Reis, Ivo M. Hennig, Andrew Wilcock · 2021 · BMJ Supportive & Palliative Care
Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment
Satoshi Furune, Chiaki Kondo, Yuko Takano, Tomoya Shimokata, Mihoko Sugishita, Ayako Mitsuma, Osamu Maeda, Yukio Ando · 2021 · International Cancer Conference Journal
Treatment of steroid-refractory immune checkpoint Inhibitor-induced intestinal pseudo-obstruction with infliximab
Cong Dai, Yu‐Hong Huang · 2023 · Revista Española de Enfermedades Digestivas
Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma
Yiran Lu, Qingchen Li, Lusi Xu, Ying Sun, Yanqing Zheng, Yanchao Wang, Ying Liu, Rui Zhang, Lin Liao, Jianjun Dong · 2023 · Journal of Cancer Research and Clinical Oncology
Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy
Katsuhisa Sekido, Shuichi Imaue, Hidetake Tachinami, Kei Tomihara, Norihito Naruto, Kentaro Yamagishi, Atsushi Ikeda, Kumiko Fujiwara, Makoto Noguchi · 2023 · Clinical Case Reports
The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland
Alekh Thapa, Anna Cowell, Adam Peters, David J. Noble, Allan James, Carolynn Lamb, Derek B. Grose, S. Vohra, Stefano Schipani, Karen E. Mactier et al. · 2024 · Clinical Oncology